Product Images Levetiracetam
View Photos of Packaging, Labels & Appearance
- Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1
- Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2
- Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3
- Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4
- Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5
- Table 15: Median Percent Reduction from Baseline in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6
- PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg/mL (473 mL Bottle) - levetiracetam fig7
- Chemical Structure - levetiracetam str
Product Label Images
The following 8 images provide visual information about the product associated with Levetiracetam NDC 65862-250 by Aurobindo Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1
The text describes a figure (Figure 1) that shows the responder rate in Study 1. The figure indicates a 250% reduction from the baseline. The text also mentions two drugs, Lovecetam 100 mg and Lovtiactan 3000 mg, which were compared to a placebo. The results show a statistically significant difference between the drugs and the placebo.*
Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2
Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3
Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4
The given text is a graph with the title "Responder Rate (250% Reduction from Baseline) in Study 4". It shows the response rate in percentages for the placebo and Levetiracetam groups. The Levetiracetam group had a significantly higher responder rate compared to the placebo group. Therefore, this graph represents the effectiveness of Levetiracetam.*
Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5
Table 15: Median Percent Reduction from Baseline in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6
The text provides a figure that shows the responder rate in PGTC seizure frequency per week in Study 7. It presents percentages of patients who responded to treatment with Levetiracetam compared to a placebo. The results highlight a statistically significant reduction in seizure frequency for patients treated with Levetiracetam.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg/mL (473 mL Bottle) - levetiracetam fig7
Chemical Structure - levetiracetam str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
